Haddon Pantel

Haddon Pantel

Auto-generated profile, based on publicly available information

Haddon Pantel


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
EFEmily Flom
Emily Flom
Kurt Samuel SchultzKurt Samuel Schultz
Kurt Samuel Schultz
HPHaddon J. Pantel
Haddon J. Pantel
ILIra L. Leeds
Ira L. Leeds
The modern rectal cancer treatment paradigm offers additional opportunities for organ preservation, most notably via total neoadjuvant therapy (TNT) and consideration for a watch-and-wait (WW) surveillance-only approach. A major barrier to widespread implementation of a WW approach to rectal cancer is the potential discordance between a clinical complete response (cCR) and a pathologic complete response (pCR). In the pre-TNT era, the identification of predictors of pCR after neoadjuvant therapy had been previously studied. However, the last meta-analysis to assess the summative evidence on this important treatment decision point predates the acceptance and dissemination of TNT strategies. The purpose of this systematic review was to assess preoperative predictors of pCR after TNT to guide the ideal selection criteria for WW in the current era. An exhaustive literature review was performed and the electronic databases Embase, Ovid, MEDLINE, PubMed, and Cochrane were comprehensively searched up to 27 June 2023. Search terms and their combinations included “rectal neoplasms”, “total neoadjuvant therapy”, and “pathologic complete response”. Only studies in English were included. Randomized clinical trials or prospective/retrospective cohort studies of patients with clinical stage 2 or 3 rectal adenocarcinoma who underwent at least 8 weeks of neoadjuvant chemotherapy in addition to chemoradiotherapy with pCR as a measured study outcome were included. In this systematic review, nine studies were reviewed for characteristics positively or negatively associated with pCR or tumor response after TNT. The results were qualitatively grouped into four categories: (1) biochemical factors; (2) clinical factors; (3) patient demographics; and (4) treatment sequence for TNT. The heterogeneity of studies precluded meta-analysis. The level of evidence was low to very low. There is minimal data to support any clinicopathologic factors that either have a negative or positive relationship to pCR and tumor response after TNT. Additional data from long-term trials using TNT is critical to better inform those considering WW approaches following a cCR.

2 November 2023 in JMIR Cancer
Verified
Journal Article
Open access
VMVictoria A Marks
Victoria A Marks
WHWalter R Hsiang
Walter R Hsiang
JNJames Nie
James Nie
WUWaez Umer
Waez Umer
AHAfash Haleem
Afash Haleem
MLMichael S Leapman
Michael S Leapman
Background: Telehealth was an important strategy for maintaining continuity of cancer care during the coronavirus pandemic and has continued to play a role in outpatient care; however, it is unknown whether services are equally available across cancer hospitals. Objective: This study aimed to assess telehealth availability at cancer hospitals for new and established patients with common cancers to contextualize the impact of access barriers to technology on overall access to health care. Methods: We conducted a national cross-sectional secret shopper study from June to November 2020 to assess telehealth availability at cancer hospitals for new and established patients with colorectal, breast, and skin (melanoma) cancer. We examined facility-level factors to determine predictors of telehealth availability. Results: Of the 312 investigated facilities, 97.1% (n=303) provided telehealth services for at least 1 cancer site. Telehealth was less available to new compared to established patients (n=226, 72% vs n=301, 97.1%). The surveyed cancer hospitals more commonly offered telehealth visits for breast cancer care (n=266, 85%) and provided lower access to telehealth for skin (melanoma) cancer care (n=231, 74%). Most hospitals (n=163, 52%) offered telehealth for all 3 cancer types. Telehealth availability was weakly correlated across cancer types within a given facility for new (r=0.16, 95% CI 0.09-0.23) and established (r=0.14, 95% CI 0.08-0.21) patients. Telehealth was more commonly available for new patients at National Cancer Institute–designated facilities, medical school–affiliated facilities, and major teaching sites, with high total admissions and below-average timeliness of care. Telehealth availability for established patients was highest at Academic Comprehensive Cancer Programs, nongovernment and nonprofit facilities, medical school–affiliated facilities, Accountable Care Organizations, and facilities with a high number of total admissions. Conclusions: Despite an increase in telehealth services for patients with cancer during the COVID-19 pandemic, we identified differences in access across cancer hospitals, which may relate to measures of clinical volume, affiliation, and infrastructure.

4 November 2024 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
AAAmit C Achhra
Amit C Achhra
ECElizabeth Chan
Elizabeth Chan
SASerina Applebaum
Serina Applebaum
MGMaggie Guerrero
Maggie Guerrero
RHRitche Hao
Ritche Hao
LBLydia Barakat
Lydia Barakat
Background: Guidelines recommend annual anal cytology-based squamous cell carcinoma of anus (SCCA) screening for men who have sex with men with HIV aged ≥35 years (eligible population). The recommended threshold for high-resolution anoscopy (HRA) depends on its availability: low-threshold (any abnormal cytology) if availability is high and high-threshold (high-grade squamous intraepithelial lesion [HSIL] on cytology) if availability is low. Methods: This was a retrospective chart review (2018–2022) at academic HIV clinics. We evaluated (1) 5-year uptake of cytology-based SCCA screening in the eligible population and (2) estimated HSIL detection rate based on our current low-threshold criteria, and if high-threshold criteria were used for HRA referral. Results: Of 432 eligible individuals, only 219 (50.7%) had at least 1 and only 113 (26%) had >1 SCCA screening tests in a median follow-up of 4 years. Seventy-four (17.1%) individuals had at least 1 abnormal anal cytology during follow-up, of whom 56 (75.6%) underwent HRA. Increasing age (≥57 years) and history of smoking negatively correlated with ever receiving screening. Anal cytology (365 tests in 206 individuals) showed 17.5% “unsatisfactory” and 26.8% with any abnormal cytology (zero with HSIL) triggering HRA referral. Only 34 individuals (7.8% of screening eligible) were ever detected with HSIL. Strictly using high-threshold criteria for HRA referral would have led to no HRA or HSIL detection. Conclusions: We noted poor uptake of screening over time, particularly in older age groups. Importantly, anal cytology performed poorly as a triage test for HRA referral, with high rates of “unsatisfactory” samples and low sensitivity for detecting HSIL.

19 May 2022 in Journal of Surgical Research
Verified
Journal Article
Closed access
PDF file
AEAndrew C. Esposito
Andrew C. Esposito
WLWilliam D. Laird
William D. Laird
YZYuqi Zhang
Yuqi Zhang
MCMarcelo Cerullo
Marcelo Cerullo
ALAndrew X. Li
Andrew X. Li
HPHaddon Pantel
Haddon Pantel

23 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SLSamantha Mei Linhares
Samantha Mei Linhares
Kurt Samuel SchultzKurt Samuel Schultz
Kurt Samuel Schultz
NCNathan A. Coppersmith
Nathan A. Coppersmith
AEAndrew C. Esposito
Andrew C. Esposito
ILIra L. Leeds
Ira L. Leeds
AMAnne Mongiu
Anne Mongiu
Introduction: Low anterior resection syndrome (LARS) can be a debilitating condition that develops after undergoing sphincter-preserving surgery for rectal cancer. Chemotherapy-induced peripheral neuropathy is a common side effect of platinum-based chemotherapy agents used as systemic therapy for rectal cancer treatment. The purpose of this study was to determine the potential relationship between CIPN and LARS. Methods: This was a retrospective review of patients who underwent a low anterior resection for rectal cancer and received systemic therapy contacted at least six months from the most recent surgery. Eligible patients were called and completed the relevant surveys over the phone or email. Results: There was a total of 42 patients who completed the surveys with 33 (79%) having major LARS. Presence of a diverting ileostomy was the only significantly differentcharacteristic in those with major LARS versus those without. CIPN was independently associated with LARS (p = 0.046) on linear regression when controlling for neoadjuvant chemoradiation, diverting ileostomy and tumor distance from the anal verge. Conclusions: Developing severe CIPN is associated with developing LARS. Further studies evaluating the etiology behind this relationship should be conducted.

1 September 2020 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
HPHaddon J. Pantel
Haddon J. Pantel
HEHulda M. Einarsdottir
Hulda M. Einarsdottir
VRVikram B. M.D. Reddy
Vikram B. M.D. Reddy
WLWalter E. Longo
Walter E. Longo